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Abstract
Objective Chronic HBV infection can lead to ‘‘immune
tolerance’’ in asymptomatic carriers (ACs), ‘‘immune
injury’’ in active chronic hepatitis (ACH) patients or
‘‘immune abnormality’’ in cirrhosis (Cir) and hepatocellu-
lar carcinoma (HCC) patients. Previous investigations
reported that chronic hepatitis presented abnormal expres-
sion of costimulatory molecules. We investigated the
costimulation profile in the liver of ACs and patients with
ACH, Cir and HCC.
Methods Patients with ACH, Cir and HCC, ACs and
normal controls were recruited into the present study. The
costimulation profiles and cytokines in the liver of patients
were investigated by Western blotting, immunohisto-
chemistry and real-time quantitative PCR. Correlations
between serum alanime aminotransferase (ALT) levels,
necroinflammation scores, cytokines and costimulatory
proteins were assessed.
Results The ACs presented decreased inflammatory and
increased inhibitory costimulation, which was negatively
correlated with inflammatory costimulatory proteins and
ALT, whereas the ACH patients exhibited increased
inflammatory costimulation and decreased inhibitory
costimulation, which was correlated with increased ALT.
The Cir patients showed both increased inhibitory and
inflammatory costimulation. The HCC patients exhibited
both decreased inhibitory and inflammatory costimulation.
Conclusion Costimulation participates in intrahepatic
immune responses, and plays important roles in immune
tolerance, immune injury and immune abnormalities in
patients with chronic HBV infection.
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ACH Active chronic hepatitis
ALT Alanime aminotransferase
CHB Chronic HBV infection
Cir Cirrhosis
CTLA-4 Cytotoxic T-lymphocyte antigen 4
DCs Dendritic cells
HBV Hepatitis B virus
HCC Hepatocellular carcinoma
HD Healthy donors
ICAM-1 Intercellular adhesion molecule-1
PD1 Programmed cell death -1
TB Total bilirubin
Introduction
Infection with hepatitis B virus (HBV) is a common
cause of chronic hepatitis. Approximately 350 million
people worldwide are chronically infected with HBV [1,
2]. Because HBV is not usually cytopathogenic by itself,
chronic HBV infection (CHB) is a dynamic state of
interaction between the virus, hepatocytes and the host’s
immune system. The natural course of CHB is generally
divided into three phases, namely the immune-tolerant
phase, the immune clearance phase and the residual or
inactive phase. In the immune-tolerant phase, subjects
with HBV infection are known as asymptomatic carriers
(ACs), presenting persistent immune tolerance against
HBV antigens but no evidence of hepatitis [2]. As the
immune-tolerant phase changes to the immune clearance
phase, patients suffer from intrahepatic inflammatory
activity and hepatitis flare. However, these inflammatory
responses do not clear HBV in hepatocytes. Persistent
HBV reproduction and inflammatory reaction in the liver
result in progressive liver disease. Patients with pro-
gressive liver diseases present a spectrum of diseases
ranging from active chronic hepatitis (ACH), through
cirrhosis (Cir) to hepatocellular carcinoma (HCC). ACH
patients exhibit ‘‘immune injury’’ and display active
hepatitis, and Cir or HCC patients present ‘‘immune
abnormalities’’ [1, 2]. Finding the distinct immune status
and investigating the immunopathophysiological differ-
ences between immune tolerance, immune injury and
immune abnormalities may clarify the immune mecha-
nism of CHB.
The innate and adaptive immune responses induce
liver diseases in CHB patients. Both immune regulatory
factors and immune cells participate in the clearing of
virus components, such as costimulatory factors, cyto-
kines, dendritic cells (DCs), HBV-specific effector T
cells, regulatory T cells, non-virus-specific lymphocytes,
natural killer cells and B cells. However, the immune
responses are extremely complex and only partially
understood [3]. Costimulatory proteins, acting as signal
peptides, contribute to signal transference among
immune cells, and are functional markers of immune
cells. When clearing a virus, the viral antigenic peptides
are first processed by antigen-presenting cells, mainly
DCs, and are bound by MHC II or MHC I complexes in
DCs. This binding contributes to DC maturation. The
matured DCs are marked by CD83?, CD80? and
CD86?. Subsequently, clonally distributed T-cell antigen
receptors on naive T cells capture the viral antigenic
peptide–MHC II or MHC I complexes on matured DCs,
and CD28 on T cells binds with CD80/CD86 on DCs.
This process induces expansion and differentiation of
clonal T cells and translates naive T cells into functional
T cells. In contrast, cytotoxic T-lymphocyte antigen 4
(CTLA-4) on T cells, acting as an inhibitory factor,
negatively regulates the CD28/CD80/CD86 pathway and
inhibits T-cell activity. Finally, the functional T cells
activate B cells and other immune cells, resulting in high
expression of CD40 and intercellular adhesion molecule-
1 (ICAM-1) and inducing secretion of inflammatory
cytokines [4–9]. In short, costimulation regulates the
immune responses.
Various authors have demonstrated that expression of
costimulatory molecules is abnormal in chronic hepatic
diseases and viral hepatitis and that abnormal costimulation
contributes to immunopathogenesis in liver diseases [4–9].
Nevertheless, their studies have obvious limitations.
Firstly, they investigated CHB immunopathophysiology on
costimulation signal pathways using animal experiments
[4, 6]. However, the resulting model of HBV infection has
not reproduced the whole disease spectrum of humans,
including ACs and ACH, Cir and HCC patients. CHB
immunopathophysiology must be demonstrated in human
liver obtained from the whole disease spectrum. Secondly,
the immune tolerance in ACs is a distinct immune state,
and its immunopathophysiology in peripheral blood is only
partly understood [10], but the intrahepatic costimulation
profile has not been investigated. Finally, the liver is an
immune-tolerant organ, in which apoptosis and degenera-
tion of functional immune cells take place, resulting in
intrahepatic immune suppression [11]. In previous papers,
different states of immunopathophysiology between the
liver and peripheral blood were defined as ‘‘immune
compartmentalization’’, which was found in investigations
on animals and humans [11–14]. Costimulatory factor
mRNA and costimulation-positive cells were detected in
liver and peripheral blood of patients [15, 16], but
costimulatory protein in human liver was not studied. In
fact, the profile of costimulatory proteins in the liver of
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patients, and not their peripheral blood, exhibits the actual
immunopathophysiology of CHB.
We hypothesized that intrahepatic costimulation in ACs
and in ACH, Cir and HCC patients was different and that
the distinct costimulation profiles might contribute to the
intrahepatic immunopathophysiology. Therefore, it was
necessary to directly detect costimulatory proteins in the
liver of patients.
Materials and methods
Liver samples and patients
Patients and normal controls, namely ACs, ACH, Cir and
HCC patients and healthy donors (HDs), were recruited
from January 7, 2002 to June 5, 2006 at four hospitals in
Jiangsu Province, China: the Second Affiliated Hospital,
Southeast University Medical School; the Surgery
Department of the First People’s Hospital of Huai’an City;
the Liver Transplantation Center of the First Affiliated
Hospital, Nanjing Medical University; and the Surgery
Department of the People’s Hospital of Tai’xing City. AC,
ACH, Cir and HCC were defined according to the criteria
reported by Lok et al. [17]. The liver tissues were obtained
from liver transplantations, surgical operations and biop-
sies. This research was carried out in accordance with the
Declaration of Helsinki (2000) of the World Medical
Association. The plan was approved by the Health Office
of Jiangsu provincial government, the Health Office of
Nanjing municipal government and all the hospital ethics
committees. All the patients or the immediate family
members of liver donors signed informed consent
documents.
Negative HBeAg patients generally have a predomi-
nance of precore and/or basal core promoter HBV
mutations that are hence either unable to express or express
low levels of HBeAg. These HBV mutations might activate
various immune responses in the host, and eventually result
in fulminant hepatitis [30]. In order to avoid the influence
of precore and the basal core promoter mutations, negative
HBeAg patients were excluded from the present study.
Antibodies and reagents
Antibodies for CD83 (H-198, SC-20083) and ICAM-1 (H-
108, SC-7891) and positive proteins for CD80 (separated
Ramos cell) and CD86 (separated Jurkat cell) were pur-
chased from Santa Cruz Biotechnology Inc. Antibodies for
CD40 (BWC02, AF632), CD28 (ADS013091, AF-342-
PB), CTLA-4 (AF-386-BP), CD80 (AAE02, AF140),
CD86 (AAE01, AF-141-NA) and b-actin and standard
proteins, namely recombinant human CD80 protein (140-
B1) and recombinant human CD86 protein (140-B2), were
purchased from R&D Inc. Pre-staining protein marker
(P7708S) was obtained from New England BioLabs,
(USA), and ABC immunochemical kits from Vector Lab-
oratories Inc. (Burlingame, CA, USA). All other reagents
were bought from Sigma.
Western blotting of costimulatory proteins in liver
The relative quantity of costimulatory proteins and of DC
marker proteins in liver were detected by Western blotting
as described by Zhong et al. [18]. Livers were homoge-
nized in lysis buffer containing 50 mm Tris HCl (pH 6.8),
2 % sodium dodecyl sulfate, 10 % glycerol, 50 mm dithi-
othreitol and 0.1 % bromophenol blue, and were diluted to
1 mg total protein/ml. Samples and lysate of liver tissue
were resolved in 8 % SDS-PAGE. Proteins were blotted
onto nitrocellulose membrane and incubated with primary
antibody and secondary antibody. Immune complexes were
visualized using an enhanced chemiluminescence substrate
by ECLTM (Amersham Pharmacia Biotech, Arlington
Heights, IL, USA). The duration of autoradiography in
































































Costimulatory protein are present in low concentrations. The duration
of autoradiography for each protein was determined at different
durations, viz. 10, 20, 40, 60, 120, 180, 240, 300, 360 and 420 min,
with the optimal duration being used for each specific protein
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each protein is shown in Table 1, and the images on the
X-ray membrane were scanned. The relative quantity of
protein was normalized to the protein quantity for each
sample using b-actin protein as an internal standard.
Costimulatory proteins are membrane proteins on immune
cells, and their content in tissue is very low. Therefore, the
common technique of Western blotting is not useful for
detecting costimulatory proteins in tissue. In the preliminary
experiment for each protein, the liver tissue obtained from a
Cir patient was firstly used to determine the optimal antibody
dilution rate. The duration of autoradiography for each protein
was then determined at different durations, viz. 10, 20, 40, 60,
120, 180, 240, 300, 360 and 420 min, with the optimal dura-
tion being used for each specific protein. The optimal
parameters are shown in Table 1.
Immunohistochemistry and histology
Histological sections of liver stained with hematoxylin and
eosin (H&E) azure and with immunohistochemical stains
of CD80, CD86, CD83, CD28, CD40, CTLA-4 and ICAM-
1 were observed by light microscopy. The liver specimens
were fixed in 4 % neutral buffered formalin, and embedded
in paraffin. Sections 6 lm thick were prepared, deparaf-
fined, and rinsed three times with 0.01 M PBS (pH 7.4).
The sections were rehydrated and incubated with 1 %
trypsinase (Sigma) for 20 min at 37 C in order to retrieve
antigen. They were then treated with 0.3 % H2O2 for
15 min to eliminate endogenous peroxidase. After blocking
with nonspecific staining, the sections were incubated with
primary antibody. The secondary antibody coupled to
horseradish peroxidase was incubated at room temperature
for 30 min, and then processed using the ABC kit of
immunoperoxidase stains. Finally, these sections were
counterstained with hematoxylin. The negative controls
were performed by omitting the first antibody.
The necroinflammatory lesions and fibrosis were graded by
the Ishak modified HAI system [19]. The maximum possible
score in this system for grading of necroinflammation was 18,
and for fibrosis was 6. The distribution of costimulatory pro-
teins in liver was revealed by immunohistochemical staining.
Real-time quantitative PCR of cytokine mRNA in liver
Real-time quantitative PCR and data analysis were performed
as described by Zhong et al. [18]. Total RNA in the liver was
extracted using an RNeasy mini kit (Generay Biotech Co.,
Shanghai, China). One lg of total RNA was reverse transcribed
in a 20 ll volume using an RT-PCR kit (Promega Corporation,
USA) according to the manufacturer’s instruction.
The primer sets were predesigned by Applied Biosystems.
The primer sequences and annealing temperatures are shown
in Table 2; and the 45-cycle PCR was performed for all
items. The cytokine mRNA was normalized to RNA loading
for each sample using b-actin mRNA as an internal standard.
The relative mRNA quantity, including interferon (IFN)-c,
interleukin (IL)-6, IL-18 and IL-10 were detected using
Engine OptionTM (MJReseach, USA) by SYBR Green I.
Statistical analysis
Data are given as means (minimal–maximal). Clinical and
immunological parameters were compared by the Kruskal–
Wallis test, Nemenyi test and M test (Friedman). Correla-
tions between ALT, necroinflammatory scores, cytokine
mRNA and costimulatory proteins were assessed using
Spearman’s rank correlation coefficient. p values \ 0.05
were considered significant.
Results
No evidence of hepatitis in ACs, but various
characteristics of liver disease in ACH, Cir and HCC
patients
The patients’ characteristics are shown in Table 3. The
ACs presented high viral loads with positive HBeAg but
Table 2 PCR primer sequences
and annealing temperature for
detecting items
Cytokine Sequence Annealing temperature (C)
IFN-c F 50-GGAGACCATCAAGGAAGACAT-30 59
R 50-GCGACAGTTCAGCCATCAC-30
IL-6 F 50-AAGCCAGAGCTGTGCAGATGAGTA-30 64
R 50-TGTCCTGCAGCCACTGGTTC-30
IL-10 F 50-GAGATGCCTTCAGCAGAGTGAAGA-30 64
R 50-AGGCTTGGCAACCCAGGTAAC-30
IL-18 F 50-GCCTGGACAGTCAGCAAGGA-30 60.5
R 50-TCTACTGGTTCAGCAGCCATCTTTA-30
b-actin F 50-TATCCTGGCTGTGCTATCCC-30 59
R 50-CCATCTCTTGCTCGAAGTCC-30
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HD 1 55/M Donor liver
from liver
transplant
Neg Neg Neg \2.70 Normal
(Nor)
Nor Nor N 1 and F 0 Surgical
operation
HD 2 47/M Donor liver
from liver
transplant
Neg Neg Neg \2.70 Nor Nor Nor N 1 and F 0 Surgical
operation
HD 3 39/M Donor liver
from liver
transplant
Neg Neg Neg \2.70 Nor Nor Nor N 0 and F 0 Surgical
operation
HD 4 27/F Donor liver
from liver
transplant
Neg Neg Neg \2.70 Nor Nor Nor N 0 and F 0 Surgical
operation
HD 5 35/M Donor liver
from liver
transplant
Neg Neg Neg \2.70 Nor Nor Nor N 1 and F 0 Surgical
operation
HD 6 32/M Donor liver
from spleen
trauma
Neg Neg Neg \2.70 Nor Nor Nor N 0 and F 0 Surgical
operation
AC 1 51/F Gastric ulcer 102.67 13.318 0.067 5.43 19.0 7.3 35.7 N 1 and F 1 Surgical
operation
AC 2 33/M Gastric
perforation
136.73 384.072 0.104 8.08 15.7 6.8 28.5 N 0 and F 0 Surgical
operation
AC 3 38/M Spleen trauma 79.42 459.150 0.166 6.91 20.1 5.3 39.8 N 1 and F 0 Surgical
operation
AC 4 24/M Duodenal ulcer
perforation
288.15 4,285.613 0.064 9.15 17.9 7.2 37.1 N 1 and F 0 Surgical
operation
AC 5 18/M HBV carrier 186.76 1,187.912 0.078 9.45 18.7 3.2 30.9 Undetection Biopsy
AC 6 36/M HBV carrier 213.07 2,237.512 0.051 8.54 21.1 7.6 32.6 Undetection Biopsy
AC 7 22/M HBV carrier 138.72 18.534 0.173 6.86 22.6 6.4 38.7 Undetection Biopsy
AC 8 26/M HBV carrier 144.39 88.969 0.249 7.81 9.1 3.1 20.8 Undetection Biopsy
AC 9 23/M HBV carrier 119.46 1,084.750 0.094 8.88 8.7 4.2 22.0 N 0 and F 0 Biopsy
AC 10 28/M HBV carrier 478.03 2,371.143 0.238 8.80 17.4 6.1 32.1 N 1 and F 0 Biopsy
ACH 1 50/M ACH, hepatic
failure
6.12 396.641 0.065 5.34 261.3 114.7 120.8 N 18 and F 2 Liver
transplant
ACH 2 46/M ACH, hepatic
failure
3.41 2.693 0.196 2.90 128.3 60.4 4,039.0 N 18 and F 2 Liver
transplant
ACH 3 38/M ACH 291.28 48.509 0.086 4.15 71.1 25.8 917.0 Undetection Biopsy
ACH 4 22/M ACH 98.12 33.375 0.079 4.46 19.4 5.1 558.6 Undetection Biopsy
ACH 5 22/M ACH 159.12 4.265 0.132 7.61 29.9 14.8 184.5 Undetection Biopsy
ACH 6 26/M ACH 148.31 42.274 0.095 7.08 20.9 8.6 323.8 Undetection Biopsy
ACH 7 21/M ACH 119.18 731.640 0.067 6.62 9.1 2.2 474.1 Undetection Biopsy
ACH 8 33/M ACH 98.14 1,347.302 0.059 8.56 17.9 2.8 130.5 Undetection Biopsy
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normal ALT, whereas ACH patients exhibited increased
ALT. Cir and HCC patients showed abnormal or normal
ALT. By histological observation, ACs exhibited no evi-
dence of hepatitis in liver or spotty lytic necrosis and
apoptosis in lobules (necroinflammatory and fibrosis scores
N 0–1 and F 0–1, respectively), similar to HDs; ACH
patients showed severe necroinflammation and slight
fibrosis (N 12–18 and F 1–2); and Cir patients presented
mild necroinflammation and definite fibrosis (N 5–9 and F
6). However, HCC patients displayed slight necroinflam-
mation and fibrosis in non-tumor tissue, namely focal lytic
necrosis, focal inflammation, piecemeal necrosis or slight
fibrosis (N 2–5 and F 0–2). The data in Table 3 show that
there was no evidence of hepatitis in ACs but various




































ACH 9 32/M ACH 105.25 564.652 0.112 8.04 12.7 3.8 151.7 Undetection Biopsy
ACH 10 27/M ACH 223.97 1,758.515 0.264 9.20 19.6 8.8 532.0 Undetection Biopsy
ACH 11 28/M ACH 231.85 7.720 0.102 2.91 23.2 11.4 140.8 N 12 and F 1 Biopsy
ACH 12 40/M ACH 69.05 152.573 0.050 4.11 173.2 55.9 252.5 N 17 and F 1 Biopsy
ACH 13 20/M ACH 59.90 0.800 0.068 5.92 35.5 11.8 109.1 N 12 and F 1 Biopsy
ACH 14 39/M ACH 80.51 560.840 0.052 8.81 25.3 11.3 96.0 N 12 and F 2 Biopsy
Cir 1 36/M Cirrhosis 153.33 2.775 0.084 6.78 40.6 8.0 43.0 N 8 and F 6 Surgical
operation
Cir 2 38/M Cirrhosis 70.12 8.59 0.183 4.84 41 16.7 66.5 N 8 and F 6 Liver
transplant
Cir 3 28/M Cirrhosis 70.96 417.763 0.108 6.18 57 23.7 96.8 N 8 and F 6 Liver
transplant
Cir 4 49/M Cirrhosis 118.96 7.159 0.063 4.30 57.7 25.9 212.6 N 9 and F 6 Surgical
operation
Cir 5 56/M Cirrhosis 31.87 15.504 0.071 3.85 117.7 56.2 39.0 N 8 and F 6 Liver
transplant
Cir 6 43/M Cirrhosis 145.73 9.49 0.064 6.11 27.8 15.6 60.0 N 5 and F 6 Surgical
operation
HCC 1 67/M Hepatocellular
carcinoma
29.87 5.504 0.038 4.53 16.7 6.8 67.4 N 5 and F 2 Surgical
operation
HCC 2 46/M Hepatocellular
carcinoma
82.84 11.203 0.115 6.20 30.1 10.0 28.3 N 3 and F 1 Surgical
operation
HCC 3 37/M Hepatocellular
carcinoma
147.56 48.483 0.094 7.84 18.6 7.5 89.0 N 5 and F 0 Surgical
operation
HCC 4 53/M Hepatocellular
carcinoma
51.34 1.147 0.152 5.88 10.0 4.6 63.0 N 3 and F 1 Surgical
operation
HCC 5 56/M Hepatocellular
carcinoma
178.68 1.31 0.052 4.04 24.5 8.4 18.0 N 2 and F 2 Surgical
operation
HCC 6 38/F Hepatocellular
carcinoma
181.75 4.312 0.043 6.34 6.7 4.5 69.0 N 3 and F 1 Surgical
operation
Protein quantity was estimated by Western blotting in the biopsy subjects AC 5–6 and ACH 3–6, mRNA quantity was detected by real-time quantitative
PCR in AC7–8 and ACH 7–10, immunohistochemistry staining was performed in AC 9–10 and ACH 11–14. All three detections, protein quantity, mRNA
quantity and immunohistochemistry staining, were performed in the surgical specimens of HD 1–6, AC 1–4, ACH 1–2, Cir 1–6 and HCC 1–6. The
necroinflammatory lesions and fibrosis were graded according to the Ishak modified HAI. The maximum possible scores for necroinflammation and
fibrosis were 18 and 6, respectively
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On correlation analysis, necroinflammatory scores in
liver were positively correlated with ALT and total bil-
irubin (TB), but negatively correlated with HBsAg and
HBV-DNA load in all CHB patients (Fig. 1). The results
shown in Fig. 1 suggest that increased ALT and TB in
peripheral blood and the severity of necroinflammation
in liver were closely interconnected, and that high
inflammatory responses partially inhibited HBV
replication.
Identification of CD80 and CD86 proteins in liver
Costimulation signals are regulated by costimulatory proteins
instead of their mRNA. However, human intrahepatic
costimulatory proteins have not previously been detected
quantitatively [4–9, 20]. In this study, we tried to identify
costimulatory proteins in liver. CD80 and CD86 proteins were
identified using the method described in Fig. 2a. The molecular
weight of CD86 protein in human liver was 80 kDa, and that of
Fig. 1 Correlation between intrahepatic scores of necroinflammation
and serum ALT, TB, HBsAg or HBV-DNA load. The histological
examination of liver tissues was performed in 24 CHB patients, 6
patients in each group. The intrahepatic scores of necroinflammation
were graded by the system of Ishak modified HAI. The correlation
coefficient between the scores of necroinflammation and ALT, TB,
HBsAg or HBV-DNA load was analyzed. The scores of necroin-
flammation in liver were positively correlated with ALT and TB, but
negatively correlated with HBsAg and HBVDNA load in all the CHB
patients
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CD80 protein was 60 kDa. In this study, we were the first to
identify costimulatory proteins in human liver tissue.
Increased markers of DC maturation in ACH and Cir
patients
The surface of DCs presents CD80, CD86 and CD83.
Matured DCs show signs of increased CD80, CD86 and
CD83, resulting in activation of T cells and contributing to
immune responses in the liver [7, 11]. Therefore, we ana-
lyzed the expression of CD80, CD86 and CD83 and
observed the localization of CD80?, CD86? and CD83?
cells in liver in order to explore the functional state of DCs.
First, we quantitatively detected the levels of CD80, CD86
and CD83 in liver by Western blotting. Figure 2b, c show
that CD80 protein levels in ACH and Cir patients were
higher than those in ACs, HDs or HCC patients (p \ 0.05),
that CD86 protein levels in ACH patients were higher than
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those in ACs, HDs, or HCC or Cir patients, that CD86
protein levels in Cir patients were higher than those in HDs
or ACs (p \ 0.05), that CD83 protein levels in Cir patients
were higher than those in HDs, ACs, or ACH or HCC
patients (p \ 0.05), and that CD83 protein levels in ACH
or HCC patients were also higher than those in HDs or ACs
(p \ 0.05). The distribution of CD80, CD83 and CD86
proteins in liver was subsequently explored by immuno-
histochemistry. CD80?, CD83? or CD86? cells appeared
in the inflammatory zone in the liver tissue of ACH
(Fig. 3a–c) or Cir patients, but few positive cells were
identified in ACs, HDs or HCC patients. ACH or Cir
patients displayed increased CD80, CD83 and CD86.
These results implied that matured CD80?, CD83? and
CD86? DCs participated in inflammatory responses in the
ACH or Cir patients.
CD28? cells participate in necroinflammation in ACH
or Cir patients, and increased CTLA-4 contributes
to immune tolerance in ACs
CD28 and CTLA-4, acting as downstream molecules of
CD80 and CD86, are attached to the surface of T cells. The
CD80, CD86/CD28 pathway provides critical costimula-
tory signals for naive T cells. Conversely, the CD80,
CD86/CTLA-4 pathway acts as a key negative regulator of
CD28-dependent T cells [21]. To evaluate the role of
costimulation on T cells, we quantitatively detected CD28
and CTLA-4 in liver. As shown in Fig. 2b, c, CD28 in
ACH patients was significantly higher than in ACs, HDs or
HCC patients (p \ 0.05), and CD28 in Cir patients was
higher than in ACs or HCC patients (p \ 0.05). CTLA-4 in
ACs was higher than in HDs or ACH or HCC patients
(p \ 0.05) and CTLA-4 in Cir patients was higher than in
ACH patients (p \ 0.05; Fig. 2b, c). As shown in Fig. 3d,
e, CD28? cells were localized in the inflammatory zone,
but low levels of CTLA-4 staining were found in the
inflammatory zone in ACH patienst. CD28? cells and
CTLA-4 staining were both markedly displayed in Cir
patients. These data showed that CD28 increased and
CTLA-4 decreased in ACH patients, that CD28 decreased
and CTLA-4 increased in ACs, and that both CD28 and
CTLA-4 increased in Cir patients. The above results sug-
gest that CD28? cells participate in inflammation in ACH
and Cir patients, and that increased CTLA-4 contributed to
immune tolerance in ACs.
CD40? cells and ICAM-1 both participate
in necroinflammation in ACH and Cir patients
Functional T cells induce activation of B cells and other
immune cells, and cause secretion of inflammatory cyto-
kines. CD40 is expressed on the surface of immune cells or
non-immune cells such as B cells, monocytes, endothelial
cells, epithelial cells, mesenchymal cells, platelets and
malignant tumor cells. Therefore, increased CD40 implies
that various immune responses occur in liver disease [22].
ICAM-1 participates in adhesion between various immune
cells. Furthermore, both CD40 and ICAM-1 contribute to
the inflammatory reaction and fibrosis generation in pro-
gressive liver disease [23]. Therefore, we quantitatively
detected the levels of CD40 and ICAM-1. Fig. 2b, c shows
that CD40 protein levels in ACH patients were higher than
in HDs or ACs or HCC patients (p \ 0.05), and CD40 in
Cir patients was higher than in HDs or ACs (p \ 0.05).
Fig. 2 Quantitative detection of costimulatory proteins or cytokine
mRNA in liver. a Identification of CD80 and CD86 in liver. Western
blotting was performed using a specific antibody against human
costimulatory protein. Recombinant human CD80 and CD86 proteins,
positive control CD80 protein (separate Ramos cell) and CD86
protein (separate Jurkat cell), negative control and liver homogenates
of human were applied to determination of CD80 and CD86 in liver
tissue. In the same western blotting, recombinant protein (Rec),
positive control (Pos), negative control (Neg) and liver homogenates
of human (Liver) were subjected to electrophoresis. In the photograph
of CD86 protein, the molecular weight of recombinant CD86 protein
was 90 kDa, and that of CD86 protein in human liver was 80 kDa. In
the photograph of CD80, the molecular weight of recombinant CD80
protein was 76 kDa, and that of CD80 protein in human liver was
60 kDa. b Representative western blotting of costimulatory proteins
in livers from six separate experiments. Homogenates obtained from
the livers in the five groups were subjected to electrophoresis. b-Actin
protein served as a protein loading standard. The molecular weight of
CD86, CD80, CD83, CD28, CTLA-4, CD40, ICAM-1 and b-actin
was 80, 60, 45, 44, 33, 48, 100 and 42 kDa, respectively. The CD80
stains in the ACH or Cir patient were darker than those in the HD, AC
or HCC subject. The CD86 stains showed that the stains in the ACH
or Cir patient were also darker than those in the HD, AC or HCC
subject. In CD83 stains, the photograph showed dark stains of CD83
in the Cir patient. The photograph showed dark stains of CD28 and
weak stains of CTLA-4 in the ACH patient. The stains of CTLA-4 in
the AC or Cir patient were darker than those in the ACH, HD or HCC
patient, whereas the stains in the ACH patient were weaker than those
in other subjects. As the CD40 photograph showed, the dark stains of
CD40 presented in the ACH or Cir patient. The ICAM-1 stains
showed that the stains in the ACH and Cir patients were darker than
those in the HD, AC and HCC subjects. c Relative quantity of
costimulatory proteins in livers of the five groups (n = 6, in each
group). The images on X-ray membrane were scanned, and the
relative quantity of protein was normalized to the protein quantity for
each sample using b-actin protein. All the parameters were shown in
this figure. The data showed increased CD80, CD86, CD83, CD28
and CD40 and decreased CTLA-4 in the ACH patient, increased
CD80, CD86, CD83, CD28, CD40 and CTLA-4 in the Cir patient,
increased CTLA-4 and decreased CD80, CD86, CD28 and CD40 in
the AC subject, and decreased CD80, CD86, CD28, CD40 and
CTLA-4 in the HCC patient. The ICAM-1 levels in the five groups
were gradually declined in the order of the ACH group, the Cir group,
the HCC group, the AC group and the HD group. d Quantitative
detection of cytokines mRNA in liver. The relative quantity of the
INFcmRNA, IL-6 mRNA, IL-18 mRNA and IL-10 mRNA in liver in
all the five groups was detected by real-time quantitative PCR. The
data showed unchanged INFcmRNA, IL-6 mRNA and IL18 mRNA
in all the five groups, and increased IL-10 mRNA in the AC or HCC
patient
b
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Figure 2c shows a gradual decrease of ICAM-1 in the five
groups in following order: ACH, Cir and HCC patients,
ACs and HDs. Increased CD40 and ICAM-1 were present
in ACH and Cir patients. As shown in Fig. 3f, g, CD40
staining and CD40? cells were enriched in the necroin-
flammatory zone, and ICAM-1 protein was found in the
hepatic sinus. CD40 and ICAM-1 were strongly observed
in the liver tissue of ACH and Cir patient. These results
implied that CD40? cells and ICAM-1 both contributed to
necroinflammation in ACH and Cir patients.
Increased IL-10 mRNA in liver of AC and HCC
patients
Cytokines are divided into inflammatory cytokines and
inhibitory cytokines. INFc, IL-6 and IL-18 participate in
acute inflammatory responses in liver. More importantly,
IL 18 expression is mainly located in the liver. Conversely,
IL-10 is an inhibitory cytokine and generally contributes to
immune suppression. Soluble cytokines are expressed by
immune cells and immediately released into the blood. The
concentration of cytokine proteins in liver is unstable, but
cytokine mRNA in tissue is stable because cytokine mRNA
is not released into the blood [18]. We therefore sought
cytokine mRNA in liver. Figure 2e shows that there were
no differences in INF-c mRNA, IL-6 mRNA and IL-18
mRNA between any of the five groups (p [ 0.05). How-
ever, IL-10 mRNA levels in ACs and HCC patients were
higher in Cir patients (p \ 0.05), and IL-10 mRNA in ACs
was higher than in ACH patients (p \ 0.05). These results
showed that INF-c mRNA, IL-6 mRNA and IL-18 mRNA
in all five groups stayed unchanged, but that IL-10 mRNA
increased in ACs and HCC patients.
Correlations between ALT and costimulatory proteins
and between costimulatory proteins in four groups
To identify the effects of costimulation on CHB, we
assessed the correlation coefficient between intrahepatic
costimulation profiles and serum ALT (see Table 4). The
ACH patients showed positive correlations between ALT
and inflammatory costimulatory proteins CD80, CD83,
CD28, CD40 and ICAM-1 (p \ 0.05), but negative corre-
lations between CTLA-4 and inflammatory costimulatory
proteins CD80, CD86, CD83, CD28, CD40 and ICAM-1
(p \ 0.05). In AC patients, CTLA-4 was negatively cor-
related with ALT, CD83, CD40 and ICAM-1 (p \ 0.05),
and IL-10 mRNA was negatively correlated with ALT
(p \ 0.05). Interestingly, ALT was positively correlated
with CD80, CD86, CD83, CD28, CD40 and ICAM-1
(p \ 0.05), although ALT was below the upper limit of
normal in all six ACs. A positive correlation between ALT
Fig. 3 Distribution of intrahepatic costimulatory proteins by immu-
nochemical staining. Immunohistochemical staining was performed
using a specific antibody against human costimulatory protein. In this
figure, seven costimulation stains in liver of the ACH patient were
shown. a Distribution of CD80 protein in liver. The hepatocytes were
surrounded by CD80? cells and inflammatory cells, 9400 magnifi-
cation. b Distribution of CD86. CD86? cells were localized in the
inflammatory zone and they surrounded the hepatocytes, 9400
magnification. c Distribution of CD83 protein by immunochemical
stains. CD83 stains mainly appeared in the inflammatory cells, and
the CD83? cells were localized in the inflammatory-necrotic zone,
9400 magnification. d Distribution of CD28 protein in the liver.
CD28? cells were enriched in the inflammatory zone, 9100
magnification. e CTLA-4 distribution in liver. Few CTLA-4 stains
were found in the inflammatory zone in the liver of the ACH patient,
9400 magnification. f Distribution CD40 in the liver. CD40 ? cells
were enriched in the necrotic zone, and CD40 stains surrounded the
hepatocytes, 9100 magnification. g ICAM-1 distribution in liver.
Most ICAM-1 stains appeared in the hepatic sinus, 9400
magnification
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and CD80 (p \ 0.05) was present in the Cir patients. In
addition, a negative correlation between ALT and IL-10
mRNA and a positive correlation between CTLA-4 and
CD83 (p \ 0.05) were displayed in the HCC patients.
These results indicate that both increased inflammatory
costimulatory proteins and decreased inhibitory costimu-
latory proteins participated in hepatitis activation in ACH
patients, and that inhibitory costimulatory proteins CTLA-
4 and IL-10 contributed to immune tolerance and main-
tained normal hepatic function in ACs.
Discussion
Costimulatory factors participate in immune responses to
HBV components, and induce maturation of DCs, activa-
tion of T cells and other immune cells, and secretion of
cytokines. Overall, the intrahepatic costimulation profile
represents opposing immunocompetences, either inflam-
matory or suppressive immune responses, which
characterize the actual immunopathophysiology of CHB
[7, 22, 24]. Our data showed decreased CTLA-4 and IL-10
and increased CD80, CD86, CD83, CD28, CD40 and
ICAM-1 in the liver of ACH patients. In contrast, a special
costimulatory expression, namely increased inhibitory
costimulatory factors and decreased inflammatory
costimulatory proteins, presented in the ACs. However, the
costimulation profiles in the Cir and HCC patients were
confusing. An inconsistent expression of costimulatory
factors, namely increased expression of both inhibitory and
inflammatory costimulatory factors, occurred in the Cir
patients. In contrast, decreased expression of both inhibi-
tory and inflammatory costimulatory factors was present in
the HCC patients. The CHB patients presented various
costimulation profiles in liver.
Previous investigations and the present study both
demonstrated that intrahepatic costimulation profiles con-
tributed to immunopathogenesis in CHB patients. Chen
et al. and Zou et al. [25, 26] investigated intrahepatic IL-
10, INF-c or programmed death 1 (PD-1) receptors in CHB
patients using immunohistochemistry and assessed the
correlation between the immunohistochemical intensity in
liver and ALT in serum. Stoop et al. [14] observed intra-
hepatic regulatory T cells using flow cytometry and
evaluated the role of these cells using correlation analysis.
Using immunohistochemistry and histology, we observed
the distribution of costimulatory proteins and necroin-
flammation scores in liver to be consistent with previous
studies. The cells with positive inflammatory costimulatory
proteins were localized in the necroinflammatory zone in
the liver of ACH and Cir patients. We therefore considered
that various inflammatory cells participate in the immu-
nopathogenesis of CHB by regulating costimulatory
proteins. In addition, intrahepatic costimulation profiles
were quantitatively detected using Western blotting, and
the relationship between the intrahepatic costimulation
Table 4 Pairwise correlation between ALT and costimulatory proteins, or between CTLA-4 and other costimulatory proteins
ALT CD80 CD86 CD83 CD28 CTLA-4 CD40 ICAM-1 IL-10 mRNA
ALT
AC group R: 1 0.756* 0.878* 0.889* 0.737* -0.855* 0.914* 0.922* -0.909*
p: 0.041 0.01 0.009 0.047 0.015 0.005 0.004 0.006
ACH group R: 1 0.807* 0.684 0.859* 0.890* -0.643 0.850* 0.738* -0.528
p: 0.026 0.067 0.014 0.009 0.084 0.016 0.047 0.141
Cir group R: 1 0.972* 0.028 0.200 -0.080 -0.522 0.311 -0.256 0.678
p: 0.001 0.958 0.704 0.881 0.288 0.549 0.625 0.069
HCC group R: 1 0.115 0.577 0.301 0.614 0.267 -0.432 -0.586 -0.752*
p: 0.826 0.231 0.562 0.194 0.609 0.393 0.222 0.042
CTLA-4
AC group R: –0.855 -0.426 -0.675 -0.776* -0.421 1 -0.842* -0.831*
*p: 0.015 0.200 0.071 0.035 0.203 0.018 0.02
ACH group R: –0.643 -0.821* -0.961* -0.903* -0.908* 1 -0.925* -0.948*
p: 0.084 0.022 0.001 0.007 0.006 0.004 0.002
Cir group R: -0.522 -0.646 -0.682 -0.341 0.585 1 0.193 -0.590
p: 0.288 0.166 0.135 0.508 0.222 0.714 0.217
HCC group R: 0.267 -0.339 0.423 0.978* 0.592 1 -0.559 0.350
p: 0.609 0.511 0.404 0.001 0.216 0.249 0.496
* p \ 0.05
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profile and serum ALT was assessed in the present study.
The results demonstrated that increased inflammatory
costimulation and decreased inhibitory costimulation both
contributed to intrahepatic necroinflammation and caused
abnormal hepatic function in ACH patients. In contrast,
increased inhibitory costimulation and decreased inflam-
matory costimulation in ACs resulted in no intrahepatic
necroinflammation and in normal serum ALT, representing
immune tolerance. However, the costimulation profiles in
the Cir and HCC patients were puzzling, and we were not
able to explain the associations in the costimulation pro-
files. Our data further revealed that the intrahepatic
costimulation profiles, instead of a single costimulatory
factor, contributed to immunopathogenesis in CHB patients
and resulted in multiple abnormalities in immune response
pathways, including DC maturation, immune cell activa-
tion and cytokine secretion.
In Asia, the majority of HBV infection is acquired
perinatally or in early childhood; a large number of patients
are therefore in the immune-tolerant phase [2]. Because of
the lack of a suitable animal model for the investigation of
the immune state of CHB patients, almost nothing is known
about the mechanism of immune tolerance and the differ-
ences between immune tolerance and immune injury. The
immune tolerance of CHB patien is still a mysterious
phenomenon. In the present study, the differences between
costimulation profiles in the liver of ACs and those of the
ACH, Cir and HCC patients were shown for the first time,
revealing some of the characteristics of immune tolerance.
Notably, opposite CTLA-4 expressions were present in
ACs and HCC patients, namely increased CTLA-4 in the
ACs and decreased CTLA-4 in the HCC patients. CTLA-4
and PD-1 inhibit T-cell activation through different path-
ways: PD-1 inhibits CD28-mediated activation of
phosphatidylinositol 3-kinase (PI3K), whereas CTLA-4
activates type II serine/threonine phosphatase PP2A. Both
CTLA-4 and PD-1 limit T-cell activation [27]. In a study
by Nakamoto et al., CD28 was highly expressed in intra-
hepatic PD-1?CTLA-4?CD8 T cells compared to CTLA-
4- CD8 T cells, and increased CD28 is a marker of T-cell
activation. By competing with CD28 for CD80 and CD86,
CTLA-4 may inhibit CD28? T-cell activation by specific
signaling pathways. Interestingly, CTLA-4 may play dif-
ferent roles in various signaling pathways in viral
infections, such as lymphocytic choriomeningitis virus,
human immunodeficiency virus and hepatitis C virus [16].
The above studies lead us to speculate that these opposing
CTLA-4 expressions in ACs and HCC patients might result
from various CTLA-4 signaling pathways for immune
tolerance of T cells or generation of HCC. However, the
mechanism remains unknown.
The present study was an observational investigation of
human liver. We would like to improve the work by
investigating further cases or by performing more tech-
niques. However, ethical principles in the clinical study
limited the acquisition of human tissue. In previous clinical
investigations, a single immunological technique was
applied to exploring intrahepatic immunopathogenesis in
CHB patients, such as immunohistochemistry in studies by
Chen et al. and Zou et al. [25, 26] or flow cytometry in
Stoop et al. [14]. However, immunohistochemical pathol-
ogists, such as Becker and Taylor [28], believe that
immunohistochemistry-based methods retain morphologi-
cal data but prove difficult to quantify, and that Western
blotting may be used for quantitative detection of protein in
tissue. In a study by Philips et al., both Western blotting
and immunohistochemistry were used to investigate
enzyme proteins in the human bladder [29]. According to
Becker’s strategy and Phillips’ measurements, we applied
two techniques, immunohistochemistry and Western blot-
ting, to explore the effects of costimulatory proteins in
liver. A limit of 6 liver specimens from each group was
used in the present study, which followed both ethical
principles and statistical principles in an observational
investigation of human tissue. In addition, we wish to
further explore the mechanism of immune tolerance and
immune injury on costimulation using analysis of signal
pathways. However, this intent is merely a wish because a
suitable animal model with the whole disease spectrum of
CHB has not been established and perfect human speci-
mens for investigation of signal pathways cannot be
obtained. For the first time, the profiles of intrahepatic
costimulation in CHB patients were investigated here,
which revealed the natural immune status of the patients. A
prominent feature of the present study was that the human
liver with the whole disease spectrum of CHB, instead of
cell culture in vitro or intervening analysis in an animal
model, was applied to investigate immunopathophysiology.
Despite the present study being preliminary, the findings
are groundbreaking in the field of chronic HBV infection.
In conclusion, various profiles of costimulation are
present in the liver of CHB patients. Costimulation par-
ticipates in immune responses in liver and plays important
roles in immune tolerance in ACs, in immune injury in
ACH patients and in immune abnormalities in Cir and
HCC patients. The multiple abnormalities in the immune
response create the immunopathogenesis of CHB patients.
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